(Press-News.org) Sophia Antipolis -- A resurgence in cardiovascular R&D is urgently needed to curb a new epidemic of cardiovascular diseases, according to leading cardiologists and industry representatives in the Cardiovascular Round Table (CRT).
The CRT is an independent forum established by the European Society of Cardiology (ESC) and comprised of cardiologists and representatives of the pharmaceutical and medical device industries. The group's views are outlined in "Championing Cardiovascular Health Innovation in Europe", published in European Heart Journal.(1)
Professor Michel Komajda (Pitié Salpetriere Hospital, Paris), past-president of the ESC and lead author of the paper, said: "Research and development in pharmacology for the management of cardiovascular diseases has been extremely powerful and efficient in Europe so far. The 30 day mortality after myocardial infarction has been more than halved in 20 years thanks to the new anti-thrombotic agents. The European economy has also benefited from the creation of high and middle profile jobs."
However, "we are worried that the period of improvement in treatment is reaching a limit," he added. The population is aging and there is an increase in comorbidities such as diabetes and obesity which induce cardiovascular diseases. At the same time research and development in CVD pharmacology is slowing down."
CVD is the leading cause of death in Europe but has not occupied a place in the top 5 active research areas since 2005. The CRT paper outlines how, compared with other medical areas, CVD related R&D is in steep decline. The authors state: "This is mostly due to the impact of complex regulation which drives up development costs and delays time-to-market for new cardiovascular drugs."
They add: "The recent closure of mainstream R&D facilities in Europe is clear evidence of an investment crisis that has to be addressed and a regulatory environment that must be simplified without compromising patients' safety which is our utmost duty."
Research and development has moved to other geographic regions and medical areas that are likely to yield better returns. There is a risk that cardiologists will not have access to the optimum treatment techniques at a time when a new CVD epidemic is gaining ground in Europe.
The authors recommend that a forum be established to discuss how to rejuvenate cardiovascular R&D in Europe. It should consist of EU representatives, national healthcare authorities and finance ministries, academia, medical societies and representatives of the pharmaceutical and medical device industries.
Their agenda should include:
Reviewing the issues driving R&D investment to other geographical and medical areas
Simplifying the clinical trials environment
Targeting EU funding through tax incentives and sponsored development programmes
Reviewing patent duration in the context of development timescales and investment
Encouraging cross-border and cross-discipline collaboration and networking.
Prof Komajda said: "As a professional society, the ESC believes it is our task to highlight how declining cardiovascular innovation threatens the availability of new treatments in Europe, a situation which leaves European citizens short of needed innovations and risks damaging the economy. We set up the CRT to increase awareness of these issues and kick start solutions."
He concludes: "A new epidemic of cardiovascular diseases is taking hold in Europe. Urgent steps are needed to halt this epidemic by removing the barriers to cardiovascular R&D in Europe."
###
Authors: ESC Press Office
Tel: +33 (0)4 92 94 77 56
Fax: +33 (0)4 92 94 86 69
Email: press@escardio.org
Notes to editor
References
(1) Championing cardiovascular health innovation in Europe. Eur Heart J (2013) doi: 10.1093/eurheartj/eht211
http://eurheartj.oxfordjournals.org/content/early/2013/07/05/eurheartj.eht211.full
About the European Society of Cardiology
The European Society of Cardiology (ESC) represents more than 80,000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.
Urgent call for cardiovascular R&D revival to halt growing CVD epidemic
2013-07-09
ELSE PRESS RELEASES FROM THIS DATE:
Poorer health for acetaminophen overdose survivors than other liver failure patients
2013-07-09
Spontaneous survivors of acetaminophen overdose have significantly lower overall health compared to survivors or transplant recipients following acute liver failure caused by non-drug induced liver injury according to a new study published online in Liver Transplantation, a journal of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. Findings show that acetaminophen overdose survivors report more days of impaired mental and physical health, and activity limitations due to poor health, pain, anxiety and depression. ...
Avoidance strategies can be valuable stress reliever, says study on work/life/school balance
2013-07-09
Toronto – If achieving a work/life balance wasn't hard enough, researchers say many of us are juggling a third factor: school.
That creates conflicts, say Bonnie Cheng, a PhD candidate at the University of Toronto's Rotman School of Management, and Julie McCarthy, an associate professor at the Rotman School and the University of Toronto Scarborough, often resulting in dissatisfaction in the area that caused that conflict. For example, skipping a family function to stay late at work can lead to less satisfaction with work.
But avoidance techniques can help, their most ...
Silicon oxide memories transcend a hurdle
2013-07-09
HOUSTON – (July 9, 2013) – A Rice University laboratory pioneering memory devices that use cheap, plentiful silicon oxide to store data has pushed them a step further with chips that show the technology's practicality.
The team led by Rice chemist James Tour has built a 1-kilobit rewritable silicon oxide device with diodes that eliminate data-corrupting crosstalk.
A paper on the new work appears this week in the journal Advanced Materials.
With gigabytes of flash memory becoming steadily cheaper, a 1k nonvolatile memory unit has little practical use. But as a proof ...
Newly identified bone marrow stem cells reveal markers for ALS
2013-07-09
Amyotrophic Lateral Sclerosis (ALS) is a devastating motor neuron disease that rapidly atrophies the muscles, leading to complete paralysis. Despite its high profile — established when it afflicted the New York Yankees' Lou Gehrig — ALS remains a disease that scientists are unable to predict, prevent, or cure.
Although several genetic ALS mutations have been identified, they only apply to a small number of cases. The ongoing challenge is to identify the mechanisms behind the non-genetic form of the disease and draw useful comparisons with the genetic forms.
Now, using ...
Did Neandertals have language?
2013-07-09
Fast-accumulating data seem to indicate that our close cousins, the Neandertals, were much more similar to us than imagined even a decade ago. But did they have anything like modern speech and language? And if so, what are the implications for understanding present-day linguistic diversity? The MPI for Psycholinguistics researchers Dan Dediu and Stephen C. Levinson argue in their paper in Frontiers in Language Sciences that modern language and speech can be traced back to the last common ancestor we shared with the Neandertals roughly half a million years ago.
The Neandertals ...
5D optical memory in glass could record the last evidence of civilization
2013-07-09
Using nanostructured glass, scientists at the University of Southampton have, for the first time, experimentally demonstrated the recording and retrieval processes of five dimensional digital data by femtosecond laser writing. The storage allows unprecedented parameters including 360 TB/disc data capacity, thermal stability up to 1000°C and practically unlimited lifetime.
Coined as the 'Superman' memory crystal, as the glass memory has been compared to the "memory crystals" used in the Superman films, the data is recorded via self-assembled nanostructures created in ...
Method to improve blood supply to engineered replacement tissues
2013-07-09
New Rochelle, NY -- Next-generation hydrogels can form synthetic scaffolds to support the formation of replacement tissues and organs in the emerging area of regenerative medicine. Embedding peptides into the hydrogels stimulates the growth of essential microvascular networks to ensure a good blood supply. Novel, cutting-edge technology in which hydrogels functionalized with laminin-derived peptides were transplanted in a mouse cornea and were shown to support cell growth and blood vessel formation is described in an article in BioResearch Open Access, a peer-reviewed open ...
Wildfires may contribute more to global warming than previously predicted
2013-07-09
LOS ALAMOS, N.M., July 9, 2013—Wildfires produce a witch's brew of carbon-containing particles, as anyone downwind of a forest fire can attest. A range of fine carbonaceous particles rising high into the air significantly degrade air quality, damaging human and wildlife health, and interacting with sunlight to affect climate. But measurements taken during the 2011 Las Conchas fire near Los Alamos National Laboratory show that the actual carbon-containing particles emitted by fires are very different than those used in current computer models, providing the potential for ...
Robotic ultrasound gives surgeon more direct control in mapping and removing kidney cancers
2013-07-09
DETROIT – While the use of ultrasound to identify tumors during kidney cancer surgery is gaining acceptance, a research team at Henry Ford Hospital has successfully taken it a step further by showing an added benefit when the procedure is done robotically.
Simply put, the kidney surgeon who performs the ultrasound robotically has direct control over the painstaking procedure instead of having to rely on an assistant for part of the task.
The researchers compared the robotic ultrasound probe to the same procedure using a laparoscopic ultrasound probe, which requires an ...
Promise and caution shown in ongoing research into stem cell treatment of strokes
2013-07-09
DETROIT – While stem-cell therapy offers great promise for the treatment of stroke, much research remains to be done to show its long-term effectiveness and to understand the potential for dangerous side effects.
These are the conclusions drawn by Henry Ford Hospital neurologists Jing Zhang, M.D., Ph.D., and Michael Chopp, Ph.D., scientific director of the Henry Ford Hospital Neuroscience Institute, in a review of their own and other current research into the next-generation treatment of one of the leading causes of death and disability around the world. The article has ...